FDA Expands Approved Use for Bladder Cancer Drug
Adults with non-muscle invasive bladder cancer now have access to a new treatment option alongside standard therapy.
Updated on Oct. 26, 2026 in Cancer
Live Poll
Do you generally trust biotechnology companies to deliver sustainable long-term value to their shareholders?
The U.S. Food and Drug Administration has granted approval for the expanded use of the drug Anktiva to treat non-muscle invasive bladder cancer that presents with papillary tumors. This decision provides a new treatment option for the majority of patients with this specific form of bladder cancer.
Why it matters
This approval significantly broadens the reach of a therapy previously limited to a rarer form of the disease. It allows more patients to access this treatment in conjunction with standard Bacillus Calmette-Guérin therapy.
The FDA approval follows a submission of additional clinical data by the manufacturer after a previous rejection. Papillary tumors are identified in 85% of patients with non-muscle invasive bladder cancer.
The players
U.S. Food and Drug Administration
The federal agency responsible for protecting public health by ensuring the safety and efficacy of medical products.
ImmunityBio
A Culver City-based biotechnology company focused on developing immunotherapies for cancer and infectious diseases.
The details
Anktiva is designed to be administered in conjunction with Bacillus Calmette-Guérin (BCG) treatment, which is a standard immunotherapy for bladder cancer. By pairing the drug with BCG, the treatment aims to enhance the immune system's response to the tumor cells. This approval marks an expansion for a medication that was first cleared for a more limited subset of non-muscle invasive bladder cancer patients in 2024.
Timeline
April 2024: Anktiva receives its initial FDA approval for a rare form of bladder cancer.
Early 2025: The FDA rejects the application for the expanded use of the drug.
October 14, 2026: The FDA approves the expanded use of Anktiva for patients with papillary tumors.
Health Landscape
This development highlights the evolving role of immunotherapies in augmenting standard bladder cancer treatments. It represents a shift toward more targeted combinations in the broader landscape of non-muscle invasive bladder cancer care.
Patients diagnosed with non-muscle invasive bladder cancer featuring papillary tumors may now have an additional pathway for care when discussed with their physician. Because treatment plans are highly specific to tumor characteristics, it is essential to consult an oncologist regarding if this combined therapy is suitable.
The takeaway
The FDA has expanded the eligible patient population for Anktiva, providing a new option for those with papillary bladder tumors. Patients and caregivers should track tumor pathology reports and discuss the current range of available immunotherapies with their specialist.
Further reading
For more information on current treatment trends, visit the Cancer section.
Source note: This article includes information reported by Los Angeles Business Journal.
Live Poll
Do you generally trust biotechnology companies to deliver sustainable long-term value to their shareholders?
